
In a global analysis, researchers found global lung cancer mortality rates are projected to increase by 43 percent in women; however, breast cancer rates should decline by 9 percent.

In a global analysis, researchers found global lung cancer mortality rates are projected to increase by 43 percent in women; however, breast cancer rates should decline by 9 percent.

How I leverage social media to raise testicular cancer awareness.

A new treatment has been approved to treat two rare forms of non-Hodgkin lymphoma.

Here are three main tips I wish I would have known during my first year of dealing with a cancer diagnosis.

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor Braftovi (encorafenib), the MEK inhibitor Mektovi (binimetinib), and the EGFR inhibitor Erbitux (cetuximab) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following one or two prior lines of treatment in the metastatic setting.

Supporting people with cancer can have an added dimension when you are a survivor yourself. Here are three ways a survivor and caregiver can practice self care.

How a cancer patient still made great memories during one of the most challenging times of his life.

Patients who receive anti-PD-1 therapies may experience delayed cutaneous side effects like lesions, eczema or psoriasis, even after treatment has ended.

Chemotherapy treatment can greatly affect balance. But, there are things that can help.

Sometimes, you're ill prepared for a scan that might change the course of your life.

Clinical trials are starting to focus more on the tumor's genetic makeup than the tumor's location.

Learning to laugh during breast cancer takes practice, but with a little effort, it can become good medicine.

All the world's a stage, including cancer wards.

Surviving cancer includes balancing the fear of suffering with the prospect of surviving.

Am I getting old or is chemo brain coming back?

There is no easy way to gain a sense of control when dealing with cancer. And we all definitely deal with it differently.

The FDA has granted a breakthrough therapy designation to the combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after at least one prior systemic therapy.

Coping with emotional and physical pain years after a spouse's death from cancer leads to more questions about his treatment.

In this week’s episode of “CURE® Talks Cancer,” we delve into immunotherapy breakthroughs and how a new series of patient summits can help individuals learn more.

We are always faced with choices on this cancer journey. Even if you end up making a wrong turn, there is always a way to get back on track.

A lunch out with friends may be more therapeutic than you think.

Take a look at the top five CURE stories of July 2018 in this video.

How just another day at work triggered thoughts of having cancer as a child.

If you can't save yourself, try focusing on the family pet, says one cancer survivor.

You are one person before the diagnosis comes, you are another person during the journey and you are different person when remission is gained. That is not to say that certain pieces of you don't remain, but I feel it nearly impossible to go through this journey unchanged.

With five immunotherapy drugs approved in the bladder cancer space, the next question researchers find themselves asking is whether these drugs would work better alone or as part of a combination for patients with metastatic disease.

The Food and Drug Administration (FDA) has approved Azedra (iobenguane I-131) for adult and pediatric patients aged 12 years or older with iobenguane scan–positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL) who require systemic anticancer therapy.

The speakers noted that certain well-known cancer centers are highly sought by organizations planning trials, due to their success at enrolling participants. That breeds competition among the hosts of trials to work with those centers and enroll their patients, which is detrimental to the pace of research overall.

I had a revelation while dress shopping. What caused my change from carefree to self-conscious regarding my lopsidedness?

After a cancer diagnosis, some people choose to look at their lives as they once were. Instead of moving forward, they become stuck in the past. Learn how this survivor found a valuable cancer lesson while cutting the grass.